Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BTG reveals more Varisolve data ahead of filing

This article was originally published in Scrip

Executive Summary

Specialist healthcare company BTG has reported positive results from VANISH-1, the second and final US pivotal Phase III trial of its varicose vein treatment Varisolve (polidocanol endovenous microfoam; PEM) and reiterated plans to submit a US NDA by the end of the year. However, it said another smaller study called VV017, investigating the use of the product following heat ablation had failed to meet the overall primary objective.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017089

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel